A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine

Journal of Viral Hepatitis

Volumn 13, Issue 4, 2006, Pages 278-288

  Zoulim, F ^a   Poynard, T ^b   Degos, F ^c   Slama, A ^d   El Hasnaoui, A ^d   Blin, P ^e,f   Mercier, F ^g   Deny, P ^h   Landais, P ⁱ   Parvaz, P ^j   Trepo, C ^a  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c BEAUJON HOSPITAL   (France)

^d GLAXOSMITHKLINE   (France)

^e Icare   (France)

^f UNIVERSITÉ DE BORDEAUX   (France)

^g STAT PROCESS   (France)

^h AVICENNE HOSPITAL   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j HOSPICES CIVILS DE LYON   (France)

more..

Author keywords

Genotype; Hepatitis B virus; Polymerase mutation; Precore mutation; Treatment resistance

Indexed keywords

AMINOTRANSFERASE; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEPATITIS B; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER FAILURE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEQUENCE ANALYSIS; SEROCONVERSION; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FRANCE; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; STATISTICS, NONPARAMETRIC;

EID: 33645086376     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00712.x     Document Type: Article

References (41)

1. Ganem D Prince AM Hepatitis B virus infection - natural history and clinical consequences N Engl J Med 2004 350 1118 1129
2. Nowak MA Bonhoeffer S Hill AM Boehme R Thomas HC McDade H Viral dynamics in hepatitis B virus infection Proc Natl Acad Sci USA 1996 30 4398 4402
3. Lai CL Chien RN Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group N Engl J Med 1998 339 61 68
4. Dienstag JL Schiff ER Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 1999 341 1256 1263
5. Schiff ER Dienstag JL Karayalcin S et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders J Hepatol 2003 38 818 826
6. Liaw YF Leung NW Chang TT et al. Effects of extended lamivudine therapy in Asian subjects with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group Gastroenterology 2000 119 172 180
7. Leung NW Lai CL Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy Hepatology 2001 33 1527 1532
8. Tassopoulos NC Volpes R Pastore G et al. Efficacy of lamivudine in subjects with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B Hepatology 1999 29 889 896
9. Honkoop P Niesters HG de Man RA Osterhaus AD Schalm SW Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns J Hepatol 1997 26 1393 1395
10. Allen MI Deslauriers M Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group Hepatology 1998 27 1670 1677
11. Gauthier J Bourne EJ Lutz MW et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in subjects with chronic hepatitis B treated with lamivudine J Infect Dis 1999 180 1757 1762
12. Tipples GA Ma MM Fischer KP Bain VG Kneteman NM Tyrrell DL Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo Hepatology 1996 24 714 717
13. Ling R Harrison TJ Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus J Gen Virol 1999 80 601 606
14. Lai CL Dienstag J Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for subjects with chronic hepatitis B Clin Infect Dis 2003 36 687 696
15. Liaw YF Chien RN Yeh CT Tsai SI Chu CM Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy Hepatology 2000 119 172 180
16. Rizzetto M Tassopoulos NC Goldin RD et al. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B J Hepatol 2005 42 173 179
17. Chang TT Lai CL Chien RN et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B J Gastroenterol Hepatol 2004 19 11 1276 1282
18. Liaw YF Sung JJ Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 2004 351 15 1521 1531
19. Di Marco V Marzano A Lampertico P et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine Hepatology 2004 40 883 891
20. Paik YH Chung HY Ryu WS et al. Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea J Hepatol 2001 35 92 98
21. Da Silva LC da Fonseca LE Carrilho FJ Alves VA Sitnik R Pinho JR Predictive factors for response to lamivudine in chronic hepatitis B Rev Inst Med Trop Sao Paulo 2000 42 189 196
22. Wakil SM Kazim SN Khan LA et al. Prevalence and profile of mutations associated with lamivudine therapy in Indian subjects with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus J Med Virol 2002 68 311 318
23. Knodell RG Ishak KG Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1981 1 431 435
24. Bedossa P Poynard T An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology 1996 24 289 293
25. Grandjacques C Pradat P Stuyver L et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity J Hepatol 2000 33 430 439
26. Chu CJ Keeffe EB Han SH et al. Prevalence of HBV precore/core promoter variants in the United States Hepatology 2003 38 3 619 628
27. Lindh M Hannoun C Dhillon AP Norkrans G Horal P Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers J Infect Dis 1999 179 4 775 782
28. Parekh S Zoulim F Ahn SH et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants J Virol 2003 77 12 6601 6612
29. Zoulim F Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection Antiviral Res 2004 64 1 15
30. Locarnini S Hatzakis A Heathcote J et al. Management of antiviral resistance in patients with chronic hepatitis B Antivir Ther 2004 9 679 693
31. Benhamou Y Bochet M Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine inhuman immunodeficiency virus-infected subjects Hepatology 1999 30 1302 1306
32. Lau DT Khokhar MF Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine Hepatology 2000 32 828 834
33. Nafa S Ahmed S Tavan D et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in subjects treated by lamivudine for chronic hepatitis B Hepatology 2000 32 1078 1088
34. Zöllner B Petersen J Schroter M Laufs R Schoder V Feucht HH 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw Lancet 2001 357 934 935
35. Akuta N Suzuki F Kobayashi M et al. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment J Hepatol 2003 38 315 321
36. Suzuki Y Arase Y Ikeda K et al. Histological improvements after a three-year lamivudine therapy in subjects with chronic hepatitis B in whom YMDD mutants did not or did develop Intervirology 2003 46 164 170
37. Dienstag JL Goldin RD Heathcote EJ et al. Histological outcome during long-term lamivudine therapy Gastroenterology 2003 124 105 117
38. Hadziyannis SJ Papatheodoridis GV Dimou E Laras A Papaioannou C Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B Hepatology 2000 32 847 851
39. Lok AS Lai CL Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 2003 125 1714 1722
40. Myers RP Tainturier MH Ratziu V et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B J Hepatol 2003 39 222 230
41. Poynard T Zoulim F Ratziu V et al. Longitudinal assessment of histology surrogate markers (Fibrotest-Actitest) during lamivudine therapy in patients with chronic hepatitis B infection Am J Gastroenterol 2005 100 1970 1980